Leveling the Playing Field in Biotechnology Investing

Subscribe to Excellence
Welcome aboard! Your submission has been received and you are now a part of the MedicalGold.ca community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.

Based in Vancouver, BioVaxys Technology Corp (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.